Adjuvant Therapy for High-Risk Stage II Colon Cancer

Introduction to Adjuvant Therapy

The American Society of Clinical Oncology recommends fluoropyrimidine monotherapy for 6 months as the standard approach for patients with high-risk stage II colon cancer, while the addition of oxaliplatin is not routinely recommended due to lack of survival benefit and increased toxicity 1, 2

The American Joint Committee on Cancer recommends that low-risk stage II patients should not receive adjuvant chemotherapy, and risk stratification is critical before considering any adjuvant therapy 3, 1, 2
High-risk features include T4 tumors, less than 12 lymph nodes examined, poorly differentiated or undifferentiated histology, lymphovascular invasion, perineural invasion, intestinal obstruction or tumor perforation at presentation, and grade BD3 tumor budding 3, 1, 2, 4, 5, 6

The National Comprehensive Cancer Network recommends that patients with T4 tumors should be offered adjuvant chemotherapy with fluoropyrimidine monotherapy as the standard approach 1, 2
For other high-risk features, adjuvant chemotherapy may be offered after thorough discussion of the small absolute benefit, and treatment should be considered more strongly when multiple high-risk factors are present 3, 1, 4

The European Society for Medical Oncology recommends fluoropyrimidine monotherapy for 6 months, with options including capecitabine or infusional 5-FU/leucovorin 3, 4, 6
Capecitabine is at least as effective as bolus 5-FU/LV with less myelosuppression but more hand-foot syndrome, and avoids central venous catheter complications 8, 6

Patients with mismatch repair deficiency or microsatellite instability-high tumors should not routinely receive fluoropyrimidine-based adjuvant chemotherapy, but may be considered for oxaliplatin-containing chemotherapy if multiple high-risk factors are present 1, 2, 5, 9

The American College of Surgeons recommends starting adjuvant chemotherapy within 8 weeks of surgery, ideally as soon as the patient has recovered 3, 8
Age alone should not alter recommendations, and elderly patients tolerate capecitabine well, while younger low-risk patients should not receive chemotherapy based solely on age 1, 2
The absolute survival benefit in stage II is small, so patient preference and comorbidities matter significantly in the final decision 8, 1

The American Society of Clinical Oncology recommends not offering adjuvant chemotherapy to low-risk stage II patients, as the harms outweigh benefits 1, 2
Oxaliplatin should not be routinely added, as the 2024 data definitively shows no survival benefit even in high-risk stage II 1, 2
MSI/MMR status should not be forgotten, as this is essential for treatment decision-making in stage II disease 8, 1, 6